Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

The goal of this clinical trial is to to evaluate the safety and efficacy of TranspoCART19 in patients with relapsed/refractory B-lymphoma. The main questions it aims to answer are: Maximum tolerated dose (MTD) Response rates Participants will be treated with the investigational medicinal product and will be followed for 36 months.

Trial Details

NCT ID
NCT06378190
Phase
PHASE1 / PHASE2
Sponsor
Instituto de Investigación Biomédica de Salamanca
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • CAR-T cells therapy
Locations (sample)
  • Barcelona, Barcelona, Spain|41.38879,2.15899
  • L'Hospitalet de Llobregat, Barcelona, Spain|41.35967,2.10028
  • Madrid, Madrid, Spain|40.4165,-3.70256
  • El Palmar, Mur, Spain|37.93939,-1.16095
  • Pamplona, Navarre, Spain|42.81687,-1.64323

Key Eligibility Criteria

  • Patients diagnosed with relapsed or refractory B-cell lymphoma (Diffuse large B-cell lymphoma, Primary diffuse large B-cell lymphoma of the Central…
  • Age over 18 years and under 80 years.
  • Functional status Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1. Patients with ECOG 2 may be included if motivated by haematolog…
  • Adequate bone marrow haematopoietic reserve.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →